#193: Diabetes risk with statins; rivaroxaban for ACS secondary prevention in Europe; vildagliptin in HF patients with diabetes; STEMI in young women

Summary: For the week ending May 31, 2013 we discuss the following top cardiology news from heartwire: • Two studies address diabetes risks with statins—one good news, one so-so • Rivaroxaban approved for ACS secondary prevention in Europe • Vildagliptin in HF patients with diabetes meets echo end point, but questions remain • Girl trouble: Rising tide of STEMI in young women "clearly not acceptable" And also, in brief: • MRI evidence of plaque progression in aliskiren-treated patients • RIPCORD: FFR during diagnostic angio may radically alter treatment plans Join us for a comprehensive review of this week's most important cardiology news.